Abstract
In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Current Pharmaceutical Design
Title:Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations
Volume: 24 Issue: 28
Author(s): Linh Tran*
Affiliation:
- Computational Chemistry Research Group, Ton Duc Thang University, Ho Chi Minh, City,Vietnam
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Abstract: In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Tran Linh *, Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations, Current Pharmaceutical Design 2018; 24 (28) . https://dx.doi.org/10.2174/1381612824666180813093420
DOI https://dx.doi.org/10.2174/1381612824666180813093420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advancement of Technology for Drug Discovery and Development – Part I
Current Topics in Medicinal Chemistry Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Antioxidant Activity and Phenolic Contents of Ajwain, Mustard, Fenugreek and Poppy Seed
Recent Innovations in Chemical Engineering Magnesium as a Neuroprotective Agent in Cerebral Ischemia
Current Medicinal Chemistry - Central Nervous System Agents Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science Comprehensive Review On Oral Disintegrating Films
Current Drug Delivery Acute Methamphetamine and Benzylpiperazine Decrease Aggression- Related Behavior in Late Adolescent Male Rats
Current Psychopharmacology The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Advances in Drug Discovery to Assess Cholinergic Neurotransmission: A Systematic Review
Current Drug Discovery Technologies Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]Carbamic acid with Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Relationships Between Alcohol Consumption, Smoking Status and Food Habits in Greek Adolescents. Vascular Implications for the Future
Current Vascular Pharmacology Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Allosteric Inhibition of G-Protein Coupled Receptor Oligomerization: Strategies and Challenges for Drug Development
Current Topics in Medicinal Chemistry Patent Review on Network-based Elderly Healthcare System in the US
Recent Patents on Computer Science Iron Leads to Memory Impairment that is Associated with a Decrease in Acetylcholinesterase Pathways
Current Neurovascular Research Expanded Temporal Binding Windows in People with Mild Cognitive Impairment
Current Alzheimer Research Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology